Compare ALKT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2005 |
| Metric | ALKT | EYPT |
|---|---|---|
| Price | $16.48 | $12.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $28.57 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,159,000.00 | $7,539,000.00 |
| Revenue This Year | $21.85 | N/A |
| Revenue Next Year | $16.90 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $13.98 | $9.41 |
| 52 Week High | $28.53 | $19.11 |
| Indicator | ALKT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 42.03 |
| Support Level | $16.10 | $11.81 |
| Resistance Level | $17.81 | $13.32 |
| Average True Range (ATR) | 0.80 | 0.96 |
| MACD | -0.13 | -0.21 |
| Stochastic Oscillator | 3.76 | 4.72 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.